Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACNS0331 reduced-dose craniospinal irradiation in standard-risk medulloblastoma
2009-010004-28Phase 3Active
- Sponsor
- Cognition Therapeutics, Inc.
- Start
- Aug 2009
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of vincristine, cisplatin, lomustine, cyclophosphamide and mesna in medulloblastoma (2 arms), sponsored by Cognition Therapeutics, Inc. Primary endpoints: Event-free survival and Overall survival. Started Aug 2009; status: active.
02
Drugs
vincristinecisplatinlomustinecyclophosphamidemesna
03
Conditions
medulloblastoma
Beyond the preview
Go deeper on 2009-010004-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010004-28.